메뉴 건너뛰기




Volumn 6, Issue 10, 2008, Pages 962-992

Acute myeloid leukemia

(20)  O'Donnell, Margaret R a   Appelbaum, Frederick R b   Coutre, Steven E c   Damon, Lloyd E d   Erba, Harry P e   Foran, James f   Lancet, Jeffrey g   Maness, Lori J h   Marcucci, Guido i   Maslak, Peter G j   Millenson, Michael k   Moore, Joseph O l   Ravandi, Farhad m   Schuening, Friedrich n   Shami, Paul o   Smith, B Douglas p   Stone, Richard M q   Tallman, Martin S r   Wang, Eunice s   White, Frank L t  


Author keywords

Acute myeloid leukemia; Chemotherapeutic agents; Cytogenetics; Leukemia treatment; NCCN clinical practice guidelines

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MYELOPEROXIDASE; RETINOIC ACID;

EID: 57449119685     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0074     Document Type: Article
Times cited : (9)

References (58)
  • 3
    • 0032784783 scopus 로고    scopus 로고
    • WHO classification of neoplastic disease of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997
    • Harris N, Jaffe E, Diebold J, et al. WHO classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
    • (1999) J Clin Oncol , vol.17 , pp. 3835-3849
    • Harris, N.1    Jaffe, E.2    Diebold, J.3
  • 4
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21:4642-4649.
    • (2003) J Clin Oncol , vol.21 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3
  • 5
    • 0037114753 scopus 로고    scopus 로고
    • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)
    • Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
    • (2002) Blood , vol.100 , pp. 4325-4336
    • Byrd, J.C.1    Mrozek, K.2    Dodge, R.K.3
  • 6
    • 33846876123 scopus 로고    scopus 로고
    • Acute myeloid leukemia carrying cytoplasmic/mutated nucleoplasmin (NPMc+ AML): Biologic and clinical correlates
    • Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleoplasmin (NPMc+ AML): biologic and clinical correlates. Blood 2007;109:874-885.
    • (2007) Blood , vol.109 , pp. 874-885
    • Falini, B.1    Nicoletti, I.2    Martelli, M.F.3    Mecucci, C.4
  • 7
    • 28444446313 scopus 로고    scopus 로고
    • Mutations in nucleophosmin (NPM) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
    • Verhaak R, Goudswaard C, Von Putten, et al. Mutations in nucleophosmin (NPM) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-3756.
    • (2005) Blood , vol.106 , pp. 3747-3756
    • Verhaak, R.1    Goudswaard, C.2    Putten, V.3
  • 8
    • 0037114829 scopus 로고    scopus 로고
    • Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
    • Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
  • 9
    • 14644438570 scopus 로고    scopus 로고
    • Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-1424. Erratum in Clin Cancer Res 2005;11:5659.
    • Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-1424. Erratum in Clin Cancer Res 2005;11:5659.
  • 10
    • 33748467435 scopus 로고    scopus 로고
    • Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8:21): A Cancer and Leukemia Group B study
    • Paschka P, Marucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8:21): a Cancer and Leukemia Group B study. J Clin Oncol 2006;24:3904-3911.
    • (2006) J Clin Oncol , vol.24 , pp. 3904-3911
    • Paschka, P.1    Marucci, G.2    Ruppert, A.S.3
  • 11
    • 33646432204 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutation in core binding factor leukemias. An Italian retrospective study
    • Cairoli R, Beghini A, Grub G, et al. Prognostic impact of c-KIT mutation in core binding factor leukemias. An Italian retrospective study. Blood 2006;107:3463-3468.
    • (2006) Blood , vol.107 , pp. 3463-3468
    • Cairoli, R.1    Beghini, A.2    Grub, G.3
  • 12
    • 33344465478 scopus 로고    scopus 로고
    • KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
    • Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:191-199.
    • (2006) Blood , vol.107 , pp. 191-199
    • Schnittger, S.1    Kohl, T.M.2    Haferlach, T.3
  • 13
    • 0023752982 scopus 로고
    • Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
    • Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72: 567-572.
    • (1988) Blood , vol.72 , pp. 567-572
    • Huang, M.E.1    Ye, Y.C.2    Chen, S.R.3
  • 14
    • 0030923479 scopus 로고    scopus 로고
    • All-trans retinoic acid in acute promylocytic leukemia
    • Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promylocytic leukemia. N EnglJ Med 1997;337:1021-1028.
    • (1997) N EnglJ Med , vol.337 , pp. 1021-1028
    • Tallman, M.S.1    Andersen, J.W.2    Schiffer, C.A.3
  • 15
    • 0037115195 scopus 로고    scopus 로고
    • All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
    • Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-4302.
    • (2002) Blood , vol.100 , pp. 4298-4302
    • Tallman, M.S.1    Andersen, J.W.2    Schiffer, C.A.3
  • 16
    • 0027368561 scopus 로고
    • Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group
    • Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-3249.
    • (1993) Blood , vol.82 , pp. 3241-3249
    • Fenaux, P.1    Le Deley, M.C.2    Castaigne, S.3
  • 17
    • 0033566639 scopus 로고    scopus 로고
    • A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
    • Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94: 1192-1200.
    • (1999) Blood , vol.94 , pp. 1192-1200
    • Fenaux, P.1    Chastang, C.2    Chevret, S.3
  • 18
    • 0030825408 scopus 로고    scopus 로고
    • Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
    • Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-1021.
    • (1997) Blood , vol.90 , pp. 1014-1021
    • Mandelli, F.1    Diverio, D.2    Avvisati, G.3
  • 19
    • 0033230342 scopus 로고    scopus 로고
    • A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia
    • Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia. Blood 1999;94:3015-3021.
    • (1999) Blood , vol.94 , pp. 3015-3021
    • Sanz, M.A.1    Martín, G.2    Rayón, C.3
  • 20
    • 0034663162 scopus 로고    scopus 로고
    • Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
    • Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-1253.
    • (2000) Blood , vol.96 , pp. 1247-1253
    • Sanz, M.A.1    Lo Coco, F.2    Martin, G.3
  • 21
    • 10744220024 scopus 로고    scopus 로고
    • Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic-acid and anthracycline monotherapy: A multicenter study by the PETHEMA group
    • Sanz MA, Martin G, Gonzalez M, et al. Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic-acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-1243.
    • (2004) Blood , vol.103 , pp. 1237-1243
    • Sanz, M.A.1    Martin, G.2    Gonzalez, M.3
  • 22
    • 50049126426 scopus 로고    scopus 로고
    • Risk-adapted treatment of acute promyelocytic leukemia: Updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy [abstract]
    • Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia: updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy [abstract], Blood 2007;110:182a.
    • (2007) Blood , vol.110
    • Sanz, M.A.1    Montesinos, P.2    Vellenga, E.3
  • 23
    • 34247369329 scopus 로고    scopus 로고
    • Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
    • Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006;24:5703-5710.
    • (2006) J Clin Oncol , vol.24 , pp. 5703-5710
    • Ades, L.1    Chevret, S.2    Raffoux, E.3
  • 24
    • 38949092914 scopus 로고    scopus 로고
    • Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results
    • Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-1084.
    • (2008) Blood , vol.111 , pp. 1078-1084
    • Ades, L.1    Sanz, M.A.2    Chevret, S.3
  • 25
    • 0030610687 scopus 로고    scopus 로고
    • Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
    • Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: 3354-3360.
    • (1997) Blood , vol.89 , pp. 3354-3360
    • Shen, Z.-X.1    Chen, G.-Q.2    Ni, J.-H.3
  • 26
    • 0032487923 scopus 로고    scopus 로고
    • Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
    • Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348.
    • (1998) N Engl J Med , vol.339 , pp. 1341-1348
    • Soignet, S.L.1    Maslak, P.2    Wang, Z.-G.3
  • 27
    • 11144355810 scopus 로고    scopus 로고
    • All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
    • Shen Z, Shiz, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101: 5328-5335.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 5328-5335
    • Shen, Z.1    Shiz, F.J.2
  • 28
    • 33646386643 scopus 로고    scopus 로고
    • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated promyelocytic leukemia
    • Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated promyelocytic leukemia. Blood 2006;107:3469-3473.
    • (2006) Blood , vol.107 , pp. 3469-3473
    • Estey, E.1    Garcia-Manero, G.2    Ferrajoli, A.3
  • 29
    • 33751116539 scopus 로고    scopus 로고
    • Optimizing treatment for elderly patients with acute promyelocytic leukemia: Is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
    • Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 2006;47:2282-2288.
    • (2006) Leuk Lymphoma , vol.47 , pp. 2282-2288
    • Tsimberidou, A.M.1    Kantarjian, H.2    Keating, M.J.3    Estey, E.4
  • 30
    • 33847188550 scopus 로고    scopus 로고
    • Strategies for advanced APL: Long-term follow-up of arsenic therapy and new approaches
    • 1:23-24
    • Tallman MS. Strategies for advanced APL: long-term follow-up of arsenic therapy and new approaches. Haematologica Reports 2005; 1:23-24.
    • Haematologica Reports 2005
    • Tallman, M.S.1
  • 31
    • 0037275493 scopus 로고    scopus 로고
    • Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count
    • Breccia M, Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Brit J Haematol 2003;120:266-270.
    • (2003) Brit J Haematol , vol.120 , pp. 266-270
    • Breccia, M.1    Carmosino, I.2    Diverio, D.3
  • 33
    • 2442588102 scopus 로고    scopus 로고
    • AIDA: The Italian way of treating APL [abstract]
    • Avvistai G, Petti MC, Lo Coco F, et al. AIDA: the Italian way of treating APL [abstract]. Blood 2003;102:142a,
    • (2003) Blood , vol.102
    • Avvistai, G.1    Petti, M.C.2    Lo Coco, F.3
  • 34
    • 16644373167 scopus 로고    scopus 로고
    • Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group
    • de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005;23:120-126.
    • (2005) J Clin Oncol , vol.23 , pp. 120-126
    • de Botton, S.1    Fawaz, A.2    Chevret, S.3
  • 35
    • 4644293319 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
    • Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:1995-1999.
    • (2004) Blood , vol.104 , pp. 1995-1999
    • Lo-Coco, F.1    Cimino, G.2    Breccia, M.3
  • 36
    • 33646404606 scopus 로고    scopus 로고
    • Age and acute myeloid leukemia
    • Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
    • (2006) Blood , vol.107 , pp. 3481-3485
    • Appelbaum, F.R.1    Gundacker, H.2    Head, D.R.3
  • 37
    • 0031905441 scopus 로고    scopus 로고
    • Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemic: A review and updated results from the Australian Leukemia Study Group
    • Bishop JF, Matthews JP, Young GA, et al. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemic: a review and updated results from the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315-321.
    • (1998) Leuk Lymphoma , vol.28 , pp. 315-321
    • Bishop, J.F.1    Matthews, J.P.2    Young, G.A.3
  • 38
    • 10244249096 scopus 로고    scopus 로고
    • A randomized investigation of high dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
    • Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-2851.
    • (1996) Blood , vol.88 , pp. 2841-2851
    • Weick, J.K.1    Kopecky, K.J.2    Appelbaum, F.R.3
  • 39
    • 0027941369 scopus 로고
    • Intensive postremission chemotherapy in adults with acute myeloid leukemia
    • Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903.
    • (1994) N Engl J Med , vol.331 , pp. 896-903
    • Mayer, R.J.1    Davis, R.B.2    Schiffer, C.A.3
  • 40
    • 34548136106 scopus 로고    scopus 로고
    • A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
    • Al-Ali HK, Brand R, Van Biezen A, et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007;21:1945-1951.
    • (2007) Leukemia , vol.21 , pp. 1945-1951
    • Al-Ali, H.K.1    Brand, R.2    Van Biezen, A.3
  • 41
    • 17544388046 scopus 로고    scopus 로고
    • Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
    • Bloomfield CD, Lawrence D, Byrd C, et al. Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-4179.
    • (1998) Cancer Res , vol.58 , pp. 4173-4179
    • Bloomfield, C.D.1    Lawrence, D.2    Byrd, C.3
  • 42
    • 0041737626 scopus 로고    scopus 로고
    • Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial
    • Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial. Blood 2003;102:1232-1240.
    • (2003) Blood , vol.102 , pp. 1232-1240
    • Suciu, S.1    Mandelli, F.2    de Witte, T.3
  • 43
    • 12944281160 scopus 로고    scopus 로고
    • High dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: Impact of cytogenetics on achieving a complete remission
    • Stein A, O'Donnell M, Slovak M, et al. High dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 2000;14:1191-1196.
    • (2000) Leukemia , vol.14 , pp. 1191-1196
    • Stein, A.1    O'Donnell, M.2    Slovak, M.3
  • 44
    • 20044371173 scopus 로고    scopus 로고
    • Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study
    • Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:482-493.
    • (2005) J Clin Oncol , vol.23 , pp. 482-493
    • Farag, S.S.1    Ruppert, A.S.2    Mrozek, K.3
  • 45
    • 28444473100 scopus 로고    scopus 로고
    • Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations
    • Döhner K, Schlenk RF, Habdank M. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-3746.
    • (2005) Blood , vol.106 , pp. 3740-3746
    • Döhner, K.1    Schlenk, R.F.2    Habdank, M.3
  • 46
    • 33644521267 scopus 로고    scopus 로고
    • Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelodysplastic syndrome
    • Kantarjian H, O'Brien S, Cortex J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelodysplastic syndrome. Cancer 2006; 106:1090-1098.
    • (2006) Cancer , vol.106 , pp. 1090-1098
    • Kantarjian, H.1    O'Brien, S.2    Cortex, J.3
  • 47
    • 33947205565 scopus 로고    scopus 로고
    • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive chemotherapy
    • Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive chemotherapy. Cancer 2007;109:1114-1124.
    • (2007) Cancer , vol.109 , pp. 1114-1124
    • Burnett, A.K.1    Milligan, D.2    Prentice, A.G.3
  • 48
    • 33745191374 scopus 로고    scopus 로고
    • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
    • Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73.
    • (2006) Blood , vol.108 , pp. 63-73
    • Farag, S.S.1    Archer, K.J.2    Mrozek, K.3
  • 49
    • 48849109720 scopus 로고    scopus 로고
    • Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study [abstract]
    • Pautas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study [abstract]. Blood 2007;110:55a.
    • (2007) Blood , vol.110
    • Pautas, C.1    Thomas, X.2    Merabet, F.3
  • 50
    • 35948934399 scopus 로고    scopus 로고
    • Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML) [abstract]
    • Cashen A, Schiller GJ, Larsen JS, et al. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML) [abstract]. Blood 2006;108:561a.
    • (2006) Blood , vol.108
    • Cashen, A.1    Schiller, G.J.2    Larsen, J.S.3
  • 51
    • 0141482004 scopus 로고    scopus 로고
    • Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    • Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386.
    • (2003) Blood , vol.102 , pp. 2379-2386
    • Kantarjian, H.1    Gandhi, V.2    Cortes, J.3
  • 52
    • 19944433802 scopus 로고    scopus 로고
    • Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    • Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-947.
    • (2005) Blood , vol.105 , pp. 940-947
    • Faderl, S.1    Gandhi, V.2    O'Brien, S.3
  • 53
    • 34250157761 scopus 로고    scopus 로고
    • Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
    • Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129-5135.
    • (2007) Blood , vol.109 , pp. 5129-5135
    • Gardin, C.1    Turlure, P.2    Fagot, T.3
  • 54
    • 33847263418 scopus 로고    scopus 로고
    • Can reduced-intensity allogeneic transplantation cure older adults with AML?
    • Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007;20: 85-90.
    • (2007) Best Pract Res Clin Haematol , vol.20 , pp. 85-90
    • Storb, R.1
  • 55
    • 33845573825 scopus 로고    scopus 로고
    • HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with e novo acute myeloid leukemia
    • Herr AL, Labopin M, Blaise D, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with e novo acute myeloid leukemia. Leukemia 2007;21:129-135.
    • (2007) Leukemia , vol.21 , pp. 129-135
    • Herr, A.L.1    Labopin, M.2    Blaise, D.3
  • 56
    • 33846924515 scopus 로고    scopus 로고
    • Prospective feasibility analysis of reduced-intensity conditioning regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
    • Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Blood 2007;109:1395-1400.
    • (2007) Blood , vol.109 , pp. 1395-1400
    • Estey, E.1    de Lima, M.2    Tibes, R.3
  • 57
    • 0036733277 scopus 로고    scopus 로고
    • Antibody targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    • Larson RA, Boogaerts M, Estey E, et al. Antibody targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1027-1636.
    • (2002) Leukemia , vol.16 , pp. 1027-1636
    • Larson, R.A.1    Boogaerts, M.2    Estey, E.3
  • 58
    • 0029015209 scopus 로고
    • A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (< 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
    • Rowe JM, Anderson JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (< 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462.
    • (1995) Blood , vol.86 , pp. 457-462
    • Rowe, J.M.1    Anderson, J.W.2    Mazza, J.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.